Blowing the Whistle at the FDA, Jan 2001, exposing Dearborn and how OspA causes immunosuppression rather than, "was a vaccine."

18 May 2017


Crymes on Video


Fungal Exosomes Inhibit Apoptosis


IDSA: "Vaccines serve the mfgs, not their victims"


BlumenthalAntiTrust Lawsuit

Exosomes, Blebs


CDC Admits Fraud, 2016
Dattwyler, 1988
Golightly, 1988
Dressler, 1994
BarbourFish, 1993
Dearborn, 1994

Pathogenic Fungi

Predicting all of GW Bush's warcrimes, Oct 2000





Nature 440, 278 (16 March 2006) | doi:10.1038/440278b

Lyme vaccine demonized by advocacy groups

Edward McSweegan1

  1. 1692 Barrister Court, Crofton, Maryland 21114, USA


As a microbiologist who managed a federal programme on Lyme disease in the 1990s, I consider that any new clinical trials of a vaccine candidate based on the protein OspA, as mentioned in your News Feature "Uphill struggle" (Nature 439, 524–525; 2006), should be confined to Europe, for three reasons.

First, Lyme disease is non-communicable, readily treatable with common antibiotics and geographically localized in the United States. Neurological cases — where treatment can be problematic — are more common in Europe and a new vaccine may reduce the costs and consequences of infection.

Second, European experience with the widely used tick-borne encephalitis virus (TBEV) vaccine may facilitate vaccine-trial recruitment and greater public acceptance of a new Lyme vaccine.

Third, Europe is a less litigious environment and is largely free of organized Lyme-patient advocacy groups. In the United States, activists have turned Lyme disease into everyone's backyard bogeyman. They have demonized experts for their views on treatment and prevention, and hired lawyers to successfully argue the dangers of vaccine-induced autoimmunity (Philadelphia Inquirer B03, July 9 2003).

The activists are already using Internet discussion groups to warn against a new vaccine. One of them recently wrote "I would encourage all Lyme patients to consider writing letters, emphasizing the lack of demand for the last vaccine, and also the fact that any future vaccines can expect a lack of cooperation, protests, legal quagmires, etc."

A careful, hysteria-free trial of the new OspA vaccine in Europe may help to undermine the opposition to it in the United States.

Extra navigation